Cognitive effects of cilostazol in Alzheimer's dementia patients with peripheral arterial occlusive disease: A case-control study
CONCLUSIONS: In AD patients with peripheral arterial occlusive disease who have received Food and Drug Administration-approved pharmacotherapy, cilostazol, as an antiplatelet, may help to preserve general cognitive function, with significant preservation in category fluency. Geriatr Gerontol Int 2023; ••: ••-••.PMID:36682741 | DOI:10.1111/ggi.14542 (Source: Atherosclerosis)
Source: Atherosclerosis - January 22, 2023 Category: Cardiology Authors: Ching-Fang Chien Ling-Chun Huang Kuan-Ying Li Yuan-Han Yang Source Type: research
Association between perioperative management of antiplatelet agents and risk of post-endoscopic submucosal dissection bleeding in early gastric cancer: an analysis of a nationwide multicenter study
Data about the detail of post-endoscopic submucosal dissection (ESD) bleeding in patients with early gastric cancer (EGC) who take antiplatelet agents (APAs), particularly in those taking thienopyridine and cilostazol, are lacking. We aimed to clarify the association between the status of APA medication and post-ESD bleeding risk. (Source: Gastrointestinal Endoscopy)
Source: Gastrointestinal Endoscopy - January 10, 2023 Category: Gastroenterology Authors: Yuko Miura, Yosuke Tsuji, Toshiyuki Yoshio, Waku Hatta, Yohei Yabuuchi, Shu Hoteya, Daisuke Kikuchi, Shigetsugu Tsuji, Yasuaki Nagami, Takuto Hikichi, Masakuni Kobayashi, Yoshinori Morita, Tetsuya Sumiyoshi, Mikitaka Iguchi, Hideomi Tomida, Takuya Inoue, Source Type: research
Association between perioperative management of antiplatelet agents and risk of post –endoscopic submucosal dissection bleeding in early gastric cancer: analysis of a nationwide multicenter study
Data are lacking regarding post –endoscopic submucosal dissection (ESD) bleeding in patients with early gastric cancer (EGC) who take antiplatelet agents (APAs), particularly in those taking thienopyridine and cilostazol. We aimed to clarify the association between the status of APA medication and post-ESD bleeding risk. (Source: Gastrointestinal Endoscopy)
Source: Gastrointestinal Endoscopy - January 10, 2023 Category: Gastroenterology Authors: Yuko Miura, Yosuke Tsuji, Toshiyuki Yoshio, Waku Hatta, Yohei Yabuuchi, Shu Hoteya, Daisuke Kikuchi, Shigetsugu Tsuji, Yasuaki Nagami, Takuto Hikichi, Masakuni Kobayashi, Yoshinori Morita, Tetsuya Sumiyoshi, Mikitaka Iguchi, Hideomi Tomida, Takuya Inoue, Tags: Original article Source Type: research
Pacemaker implantation for persistent sinus node dysfunction in a patient with COVID ‐19
AbstractA 46-year-old woman was admitted with coronavirus disease-2019 infection. Symptomatic sinus bradycardia occurred, followed by congestive heart failure. Therapeutics such as isoproterenol, theophylline, and cilostazol could not safely improve her symptoms. She underwent pacemaker implantation 53 days after admission. Atrial pacing remained was at 60% after 6 months. (Source: Clinical Case Reports)
Source: Clinical Case Reports - January 6, 2023 Category: General Medicine Authors: Tsuyoshi Ota,
Katsunori Okajima,
Yuichi Nagamatsu,
Tomoyuki Nakanishi,
Yasuhiro Kaetsu,
Takahiro Sawada,
Takeaki Shirai,
Rio Shiraki,
Makoto Kadotani,
Yoshio Onishi Tags: CASE REPORT Source Type: research
Exploration of treatments for subarachnoid hemorrhage
J Biomed Res (Middlet). 2022;3(1):48-55.ABSTRACTSubarachnoid hemorrhage (SAH) continues to be a leading cause of morbidity and mortality, with cerebral vasospasm as a common etiology of worse clinical progression. The purpose of this study was to evaluate and review the current literature concerning the effective treatment of SAH. The treatment options for SAH are expanding as new therapeutic targets are identified. Nimodipine is the primary medication prescribed due to its neuroprotective properties. In addition, certain drugs can enhance lymphatic flow and influence the recovery process, such as Dexmedetomidine, SSRIs, a...
Source: Biomed Res - January 2, 2023 Category: Research Authors: Mohammad Reza Hosseini Siyanaki Brandon Lucke-Wold Majid Khan Source Type: research
Exploration of treatments for subarachnoid hemorrhage
J Biomed Res (Middlet). 2022;3(1):48-55.ABSTRACTSubarachnoid hemorrhage (SAH) continues to be a leading cause of morbidity and mortality, with cerebral vasospasm as a common etiology of worse clinical progression. The purpose of this study was to evaluate and review the current literature concerning the effective treatment of SAH. The treatment options for SAH are expanding as new therapeutic targets are identified. Nimodipine is the primary medication prescribed due to its neuroprotective properties. In addition, certain drugs can enhance lymphatic flow and influence the recovery process, such as Dexmedetomidine, SSRIs, a...
Source: Biomed Res - January 2, 2023 Category: Research Authors: Mohammad Reza Hosseini Siyanaki Brandon Lucke-Wold Majid Khan Source Type: research
Reversal of spatial memory impairment by phosphodiesterase 3 inhibitor cilostazol is associated with reduced neuroinflammation and increased cerebral glucose uptake in aged male mice
The nucleotide second messenger 3′, 5′-cyclic adenosine monophosphate (cAMP) and 3′, 5′-cyclic guanosine monophosphate (cGMP) mediate fundamental functions of the brain, including learning and memory. Phosphodiesterase 3 (PDE3) can hydrolyze both cAMP and cGMP and appears to be involved in the regulation of their contents in cells. We previously demonstrated that long-term administration of cilostazol, a PDE3 inhibitor, maintained good memory performance in aging mice. Here, we report on studies aimed at determining whether cilostazol also reverses already-impaired memory in aged male mice. One month of oral 1.5% c...
Source: Frontiers in Pharmacology - December 21, 2022 Category: Drugs & Pharmacology Source Type: research
Sex differences in the progression of cerebral microbleeds in patients with concomitant cerebral small vessel disease
ConclusionThe progression of CMB over 2 years was significantly greater in women than in men. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - December 20, 2022 Category: Neurology Source Type: research
Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease
to assess the effects of cilostazol on pain-free walking distance in PAD patients with IC at 3 and 6 months in a real world, prospective, observational study. We included 1015 PAD patients presenting with IC (... (Source: BMC Research Notes)
Source: BMC Research Notes - December 20, 2022 Category: Research Authors: Niki Katsiki, Nikolaos Tentolouris, Georgios Marakomichelakis, Dimitrios Richter, Athanasios Giannoukas, Panagiota Koufaki and Nikolaos Papanas Tags: Research Note Source Type: research
Cilostazol: Several issues to be considered about the safety profile
Nefrologia (Engl Ed). 2022 Nov 24:S2013-2514(22)00136-5. doi: 10.1016/j.nefroe.2021.06.007. Online ahead of print.NO ABSTRACTPMID:36437199 | DOI:10.1016/j.nefroe.2021.06.007 (Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia)
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - November 27, 2022 Category: Urology & Nephrology Authors: Hiroshi Ito Source Type: research
Cilostazol as a Treatment for COVID Toes: A Case Report
We describe the case of a fully vaccinated, 56-year-old woman with no prior diagnosis of COVID-19 who developed pernio-like lesions many months after being vaccinated. Her skin lesions resolved after treatment with cilostazol, suggesting that this medication may be a viable treatment for pernio in the setting of COVID-19 infection. (Source: Annals of Vascular Surgery)
Source: Annals of Vascular Surgery - November 24, 2022 Category: Surgery Authors: Patton McClelland, Bruce Gray Tags: Case Report Source Type: research
Cilostazol as a Treatment for COVID Toes: A Case Report
We describe the case of a fully vaccinated, 56-year-old woman with no prior diagnosis of COVID-19 who developed pernio-like lesions many months after being vaccinated. Her skin lesions resolved after treatment with cilostazol, suggesting that this medication may be a viable treatment for pernio in the setting of COVID-19 infection. (Source: Annals of Vascular Surgery)
Source: Annals of Vascular Surgery - November 24, 2022 Category: Surgery Authors: Patton McClelland, Bruce H. Gray Tags: Case Report Source Type: research
Inhibition of platelet activation suppresses reactive enteric glia and mitigates intestinal barrier dysfunction during sepsis
CONCLUSIONS: The inhibition of platelet activation is related to the suppression of CD40L-CD40-TRAF6 signaling pathway and the reduction of EGCs activation, which promotes intestinal barrier function and survival in sepsis mice. These results might provide a potential therapeutic strategy and a promising target for sepsis.PMID:36401163 | DOI:10.1186/s10020-022-00562-w (Source: Molecular Medicine)
Source: Molecular Medicine - November 19, 2022 Category: Molecular Biology Authors: Bo Cheng Mengyu Du Shuxuan He Lan Yang Xi Wang Hui Gao Haiqing Chang Wei Gao Yan Li Qiang Wang Yansong Li Source Type: research
Inhibition of platelet activation suppresses reactive enteric glia and mitigates intestinal barrier dysfunction during sepsis
CONCLUSIONS: The inhibition of platelet activation is related to the suppression of CD40L-CD40-TRAF6 signaling pathway and the reduction of EGCs activation, which promotes intestinal barrier function and survival in sepsis mice. These results might provide a potential therapeutic strategy and a promising target for sepsis.PMID:36401163 | PMC:PMC9673322 | DOI:10.1186/s10020-022-00562-w (Source: Molecular Medicine)
Source: Molecular Medicine - November 19, 2022 Category: Molecular Biology Authors: Bo Cheng Mengyu Du Shuxuan He Lan Yang Xi Wang Hui Gao Haiqing Chang Wei Gao Yan Li Qiang Wang Yansong Li Source Type: research
